Pedro C. Barata

Pulmonary and Respiratory Medicine · 2017

A researcher in the Science corpus: 1 paper; trusts 7 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Pedro C. Barata trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. I. Frank
  2. M. Blute
  3. B. Leibovich
  4. D. Pardoll
  5. John C. Cheville
  6. Christine M. Lohse

Papers from Pedro C. Barata's perspective

Ordered by how strongly the researchers Pedro C. Barata trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (New England Journal of Medicine)
  2. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. (The Lancet)
  3. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia (American Journal of Surgical Pathology)
  4. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. (The Lancet Oncology)
  5. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. (New England Journal of Medicine)
  6. Comprehensive Molecular Characterization of Papillary Renal Cell Carcinoma (New England Journal of Medicine)
  7. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma (Cancer)
  8. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. (New England Journal of Medicine)
  9. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  10. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)

Their papers